Adial Pharmaceuticals announced on June 17, 2025, the pricing of a public offering for the purchase and sale of 11,100,000 shares of common stock, or common stock equivalents. The offering also includes Series D warrants to purchase up to 11,100,000 shares and Series E warrants to purchase up to 8,325,000 shares.
The combined offering price for each share and accompanying warrants is $0.3251. This transaction is expected to result in aggregate net proceeds of approximately $3.0 million for the company.
Adial Pharmaceuticals intends to use the net proceeds from this offering for working capital and general corporate purposes. This capital raise is crucial for funding the company's ongoing clinical development programs and operational needs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.